Application of Perinatal Derivatives on Oncological Preclinical Models: A Review of Animal Studies
Authors
Teixo, RicardoPires, Ana Salomé

Pereira, Eurico

Serambeque, Beatriz

Marques, Inês Alexandra

Laranjo, Mafalda

Mojsilović, Slavko

Gramignoli, Roberto

Ponsaerts, Peter

Schoeberlein, Andreina

Botelho, Maria Filomena

Article (Published version)
Metadata
Show full item recordAbstract
The increasing cancer incidence has certified oncological management as one of the most critical challenges for the coming decades. New anticancer strategies are still needed, despite the significant advances brought to the forefront in the last decades. The most recent, promising therapeutic approaches have benefitted from the application of human perinatal derivatives (PnD), biological mediators with proven benefits in several fields beyond oncology. To elucidate preclinical results and clinic outcomes achieved in the oncological field, we present a narrative review of the studies resorting to animal models to assess specific outcomes of PnD products. Recent preclinical evidence points to promising anticancer effects offered by PnD mediators isolated from the placenta, amniotic membrane, amniotic fluid, and umbilical cord. Described effects include tumorigenesis prevention, uncontrolled growth or regrowth inhibition, tumor homing ability, and adequate cell-based delivery capacity. Fu...rthermore, PnD treatments have been described as supportive of chemotherapy and radiological therapies, particularly when resistance has been reported. However, opposite effects of PnD products have also been observed, offering support and trophic effect to malignant cells. Such paradoxical and dichotomous roles need to be intensively investigated. Current hypotheses identify as explanatory some critical factors, such as the type of the PnD biological products used or the manufacturing procedure to prepare the tissue/cellular treatment, the experimental design (including human-relevant animal models), and intrinsic pathophysiological characteristics. The effective and safe translation of PnD treatments to clinical practice relies on the collaborative efforts of all researchers working with human-relevant oncological preclinical models. However, it requires proper guidelines and consensus compiled by experts and health workers who accurately describe the methodology of tissue collection, PnD isolation, manufacturing, preservation, and delivery to the final user.
Keywords:
perinatal derivatives / cancer / preclinical studies / animal modelsSource:
International Journal of Molecular Sciences, 2022, 23, 15, 8570-Funding / projects:
- This research was funded by the FOUNDATION FOR SCIENCE AND TECHNOL-OGY (FCT), Portugal through the Strategic Projects UID/NEU/04539/2019 UIDB/04539/2020,UIDP/04539/2020
- COMPETE-FEDER, reference number POCI-01-0145-FEDER-007440
- Scholarship grants from FCT and European Social Funding to R.T. (SFRH/BD/116794/2016), I.A.M.(SFRH/BD/136973/2018), B.S. (2020.07672.BD) and E.P. (2021.05543.BD)
Collections
Institution/Community
Institut za medicinska istraživanjaTY - JOUR AU - Teixo, Ricardo AU - Pires, Ana Salomé AU - Pereira, Eurico AU - Serambeque, Beatriz AU - Marques, Inês Alexandra AU - Laranjo, Mafalda AU - Mojsilović, Slavko AU - Gramignoli, Roberto AU - Ponsaerts, Peter AU - Schoeberlein, Andreina AU - Botelho, Maria Filomena PY - 2022 UR - http://rimi.imi.bg.ac.rs/handle/123456789/1252 AB - The increasing cancer incidence has certified oncological management as one of the most critical challenges for the coming decades. New anticancer strategies are still needed, despite the significant advances brought to the forefront in the last decades. The most recent, promising therapeutic approaches have benefitted from the application of human perinatal derivatives (PnD), biological mediators with proven benefits in several fields beyond oncology. To elucidate preclinical results and clinic outcomes achieved in the oncological field, we present a narrative review of the studies resorting to animal models to assess specific outcomes of PnD products. Recent preclinical evidence points to promising anticancer effects offered by PnD mediators isolated from the placenta, amniotic membrane, amniotic fluid, and umbilical cord. Described effects include tumorigenesis prevention, uncontrolled growth or regrowth inhibition, tumor homing ability, and adequate cell-based delivery capacity. Furthermore, PnD treatments have been described as supportive of chemotherapy and radiological therapies, particularly when resistance has been reported. However, opposite effects of PnD products have also been observed, offering support and trophic effect to malignant cells. Such paradoxical and dichotomous roles need to be intensively investigated. Current hypotheses identify as explanatory some critical factors, such as the type of the PnD biological products used or the manufacturing procedure to prepare the tissue/cellular treatment, the experimental design (including human-relevant animal models), and intrinsic pathophysiological characteristics. The effective and safe translation of PnD treatments to clinical practice relies on the collaborative efforts of all researchers working with human-relevant oncological preclinical models. However, it requires proper guidelines and consensus compiled by experts and health workers who accurately describe the methodology of tissue collection, PnD isolation, manufacturing, preservation, and delivery to the final user. T2 - International Journal of Molecular Sciences T1 - Application of Perinatal Derivatives on Oncological Preclinical Models: A Review of Animal Studies IS - 15 SP - 8570 VL - 23 DO - 10.3390/ijms23158570 ER -
@article{ author = "Teixo, Ricardo and Pires, Ana Salomé and Pereira, Eurico and Serambeque, Beatriz and Marques, Inês Alexandra and Laranjo, Mafalda and Mojsilović, Slavko and Gramignoli, Roberto and Ponsaerts, Peter and Schoeberlein, Andreina and Botelho, Maria Filomena", year = "2022", abstract = "The increasing cancer incidence has certified oncological management as one of the most critical challenges for the coming decades. New anticancer strategies are still needed, despite the significant advances brought to the forefront in the last decades. The most recent, promising therapeutic approaches have benefitted from the application of human perinatal derivatives (PnD), biological mediators with proven benefits in several fields beyond oncology. To elucidate preclinical results and clinic outcomes achieved in the oncological field, we present a narrative review of the studies resorting to animal models to assess specific outcomes of PnD products. Recent preclinical evidence points to promising anticancer effects offered by PnD mediators isolated from the placenta, amniotic membrane, amniotic fluid, and umbilical cord. Described effects include tumorigenesis prevention, uncontrolled growth or regrowth inhibition, tumor homing ability, and adequate cell-based delivery capacity. Furthermore, PnD treatments have been described as supportive of chemotherapy and radiological therapies, particularly when resistance has been reported. However, opposite effects of PnD products have also been observed, offering support and trophic effect to malignant cells. Such paradoxical and dichotomous roles need to be intensively investigated. Current hypotheses identify as explanatory some critical factors, such as the type of the PnD biological products used or the manufacturing procedure to prepare the tissue/cellular treatment, the experimental design (including human-relevant animal models), and intrinsic pathophysiological characteristics. The effective and safe translation of PnD treatments to clinical practice relies on the collaborative efforts of all researchers working with human-relevant oncological preclinical models. However, it requires proper guidelines and consensus compiled by experts and health workers who accurately describe the methodology of tissue collection, PnD isolation, manufacturing, preservation, and delivery to the final user.", journal = "International Journal of Molecular Sciences", title = "Application of Perinatal Derivatives on Oncological Preclinical Models: A Review of Animal Studies", number = "15", pages = "8570", volume = "23", doi = "10.3390/ijms23158570" }
Teixo, R., Pires, A. S., Pereira, E., Serambeque, B., Marques, I. A., Laranjo, M., Mojsilović, S., Gramignoli, R., Ponsaerts, P., Schoeberlein, A.,& Botelho, M. F.. (2022). Application of Perinatal Derivatives on Oncological Preclinical Models: A Review of Animal Studies. in International Journal of Molecular Sciences, 23(15), 8570. https://doi.org/10.3390/ijms23158570
Teixo R, Pires AS, Pereira E, Serambeque B, Marques IA, Laranjo M, Mojsilović S, Gramignoli R, Ponsaerts P, Schoeberlein A, Botelho MF. Application of Perinatal Derivatives on Oncological Preclinical Models: A Review of Animal Studies. in International Journal of Molecular Sciences. 2022;23(15):8570. doi:10.3390/ijms23158570 .
Teixo, Ricardo, Pires, Ana Salomé, Pereira, Eurico, Serambeque, Beatriz, Marques, Inês Alexandra, Laranjo, Mafalda, Mojsilović, Slavko, Gramignoli, Roberto, Ponsaerts, Peter, Schoeberlein, Andreina, Botelho, Maria Filomena, "Application of Perinatal Derivatives on Oncological Preclinical Models: A Review of Animal Studies" in International Journal of Molecular Sciences, 23, no. 15 (2022):8570, https://doi.org/10.3390/ijms23158570 . .